Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb’s Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Related Questions
How will the FDA's priority review decision affect Bristol Myers Squibb's (BMY) stock price in the short term?
How does the acceptance for priority review in MZL compare to recent FDA milestones for Breyanzi in other indications?
Will this development influence analyst coverage or earnings forecasts for Bristol Myers Squibb?
What are the risks if the FDA does not grant full approval after the priority review?
What are the implications for the company's pipeline valuation and overall R&D spending expectations?
What is the potential market size for Breyanzi in relapsed or refractory marginal zone lymphoma and its impact on BMY's revenue outlook?
What price reaction can be expected from the market given the 65 sentiment score and the designation for a fifth cancer type?
Could this news trigger short‑term trading opportunities or options strategies around the stock?
How might the acceptance for priority review affect the licensing and partnership dynamics with biotech collaborators?
How does this regulatory progress position Bristol Myers Squibb against competitors' CAR‑T therapies targeting similar hematologic malignancies?